Patents by Inventor Walter F. Lima

Walter F. Lima has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • OLIGOMER-CONJUGATE COMPLEXES AND THEIR USE
    Publication number: 20220025370
    Abstract: Oligonucleotides, chemically-modified oligonucleotides, and oligonucleotide-conjugate complexes for use in research, diagnostics, and/or therapeutics are described herein. In some embodiments, oligonucleotides comprising a stabilized phosphate moiety covalently attached to the 5?-terminal nucleoside are provided.
    Type: Application
    Filed: July 1, 2021
    Publication date: January 27, 2022
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Thazha P. Prakash, Eric E. Swayze, Walter F. Lima, Garth A. Kinberger
  • Oligomer-conjugate complexes and their use
    Patent number: 11104899
    Abstract: Oligonucleotides, chemically-modified oligonucleotides, and oligonucleotide-conjugate complexes for use in research, diagnostics, and/or therapeutics are described herein. In some embodiments, oligonucleotides comprising a stabilized phosphate moiety covalently attached to the 5?-terminal nucleoside are provided.
    Type: Grant
    Filed: June 18, 2018
    Date of Patent: August 31, 2021
    Assignee: lonis Pharmaceuticals, Inc.
    Inventors: Thazha P. Prakash, Eric E. Swayze, Walter F. Lima, Garth A. Kinberger
  • Single-Stranded RNAI Oligonucleotides Targeting APOC-III
    Publication number: 20200270609
    Abstract: The present disclosure pertains generally to chemically-modified oligonucleotides for use in research, diagnostics, and/or therapeutics. In certain embodiments, the present disclosure describes compounds and methods for the modulation of a target nucleic acid. In certain embodiments, the present disclosure describes compounds and methods for the modulation of Apoliprotein C-III expression.
    Type: Application
    Filed: March 9, 2020
    Publication date: August 27, 2020
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Thazha P. Prakash, Walter F. Lima, Garth A. Kinberger, Heather Murray, Eric E. Swayze, Stanley T. Crooke
  • OLIGOMER-CONJUGATE COMPLEXES AND THEIR USE
    Publication number: 20190136234
    Abstract: Oligonucleotides, chemically-modified oligonucleotides, and oligonucleotide-conjugate complexes for use in research, diagnostics, and/or therapeutics are described herein. In some embodiments, oligonucleotides comprising a stabilized phosphate moiety covalently attached to the 5?-terminal nucleoside are provided.
    Type: Application
    Filed: June 18, 2018
    Publication date: May 9, 2019
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Thazha P. Prakash, Eric E. Swayze, Walter F. Lima, Garth A. Kinberger
  • SINGLE-STRANDED RNAI OLIGONUCLEOTIDES TARGETING APOC-III
    Publication number: 20190127737
    Abstract: The present disclosure pertains generally to chemically-modified oligonucleotides for use in research, diagnostics, and/or therapeutics. In certain embodiments, the present disclosure describes compounds and methods for the modulation of a target nucleic acid. In certain embodiments, the present disclosure describes compounds and methods for the modulation of Apoliprotein C-III expression.
    Type: Application
    Filed: November 5, 2018
    Publication date: May 2, 2019
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Thazha P. Prakash, Walter F. Lima, Garth A. Kinberger, Heather Murray, Eric E. Swayze, Stanley T. Crooke
  • Oligomer-conjugate complexes and their use
    Patent number: 10023861
    Abstract: Oligonucleotides, chemically-modified oligonucleotides, and oligonucleotide-conjugate complexes for use in research, diagnostics, and/or therapeutics are described herein. In some embodiments, oligonucleotides comprising a stabilized phosphate moiety covalently attached to the 5?-terminal nucleoside are provided.
    Type: Grant
    Filed: August 29, 2012
    Date of Patent: July 17, 2018
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Thazha P. Prakash, Eric E. Swayze, Walter F. Lima, Garth A. Kinberger
  • Oligomeric compounds and methods
    Patent number: 9738895
    Abstract: The present invention provides oligomeric compounds and uses thereof. In certain embodiments, such oligomeric compounds are useful as antisense compounds. Certain such antisense compounds are useful as RNase H antisense compounds or as RNAi compounds.
    Type: Grant
    Filed: February 10, 2015
    Date of Patent: August 22, 2017
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Eric E. Swayze, Balkrishen Bhat, Walter F. Lima, Thazha P. Prakash, Garth A. Kinberger
  • 5?-end derivatives
    Patent number: 9725479
    Abstract: The present invention provides compounds of formula (1). Another aspect of the invention relates to a method of inhibiting the expression of a gene in call, the method comprising (a) contacting an oligonucleotide of the invention with the cell; and (b) maintaining the cell from step (a) for a time sufficient to obtain degradation of the mRNA of the target gene.
    Type: Grant
    Filed: April 22, 2011
    Date of Patent: August 8, 2017
    Assignees: Ionis Pharmaceuticals, Inc., Alaylam Pharmacueuticals, Inc.
    Inventors: Muthiah Manoharan, Kallanthottathil G. Rajeev, Ivan Zlatev, Eric E. Swayze, Thazha P. Prakash, Walter F. Lima
  • COMPOSITIONS AND METHODS FOR MODULATION OF TARGET NUCLEIC ACIDS
    Publication number: 20160122761
    Abstract: The present disclosure pertains generally to chemically-modified oligonucleotides for use in research, diagnostics, and/or therapeutics. In certain embodiments, the present disclosure describes compounds and methods for the modulation of a target nucleic acid. In certain embodiments, the present disclosure describes compounds and methods for the modulation of Apoliprotein C-III expression.
    Type: Application
    Filed: June 23, 2014
    Publication date: May 5, 2016
    Applicant: Isis Pharmaceuticals, Inc.
    Inventors: Thazha P. Prakash, Walter F. Lima, Garth A. Kinberger, Heather Murray, Eric E. Swayze, Stanley T. Crooke
  • OLIGOMERIC COMPOUNDS AND METHODS
    Publication number: 20150167006
    Abstract: The present invention provides oligomeric compounds and uses thereof. In certain embodiments, such oligomeric compounds are useful as antisense compounds. Certain such antisense compounds are useful as RNase H antisense compounds or as RNAi compounds.
    Type: Application
    Filed: February 10, 2015
    Publication date: June 18, 2015
    Applicant: ISIS PHARMACEUTICALS, INC.
    Inventors: Eric E. Swayze, Balrkishen Bhat, Walter F. Lima, Thazha P. Prakash, Garth A. Kinberger
  • Oligomeric compounds and methods
    Patent number: 8987435
    Abstract: The present invention provides oligomeric compounds and uses thereof. In certain embodiments, such oligomeric compounds are useful as antisense compounds. Certain such antisense compounds are useful as RNase H antisense compounds or as RNAi compounds.
    Type: Grant
    Filed: October 23, 2009
    Date of Patent: March 24, 2015
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Eric E. Swayze, Balkrishen Bhat, Walter F. Lima, Thazha P. Prakash, Garth A. Kinberger
  • OLIGOMER-CONJUGATE COMPLEXES AND THEIR USE
    Publication number: 20150018540
    Abstract: Oligonucleotides, chemically-modified oligonucleotides, and oligonucleotide-conjugate compl in research, diagnostics, and/or therapeutics are described herein.
    Type: Application
    Filed: August 29, 2012
    Publication date: January 15, 2015
    Applicant: ISIS PHARMACEUTICALS, INC.
    Inventors: Thazha P. Prakash, Eric E. Swayze, Walter F. Lima, Garth A. Kinberger
  • COMPOSITIONS AND METHODS FOR OPTIMIZING CLEAVAGE OF RNA BY RNASE H
    Publication number: 20150011001
    Abstract: The present invention provides compositions and methods for the optimization of cleavage of RNA species by RNase H. In some embodiments, the invention provides oligonucleotides that possess two or more regions of differing conformation, and at least one transitional nucleobase positioned between the regions that is capable of modulating transfer of the helical conformation characteristic of the region bound to the 3? hydroxy thereof, to the region bound to the 5? hydroxyl thereof.
    Type: Application
    Filed: June 13, 2014
    Publication date: January 8, 2015
    Applicant: ISIS PHARMACEUTICALS, INC.
    Inventors: Michael T. Migawa, Walter F. Lima, Eric E. Swayze, Joshua Nichols, Hongjiang Wu, Thazha P. Prakash, Tadeusz Krzysztof Wyrzykiewicz, Balkrishen Bhat, Stanley T. Crooke
  • Compositions and methods for optimizing cleavage of RNA by RNase H
    Patent number: 8790919
    Abstract: The present invention provides compositions and methods for the optimization of cleavage of RNA species by RNase H. In some embodiments, the invention provides oligonucleotides that possess two or more regions of differing conformation, and at least one transitional nucleobase positioned between the regions that is capable of modulating transfer of the helical conformation characteristic of the region bound to the 3?hydroxy thereof, to the region bound to the 5? hydroxyl thereof.
    Type: Grant
    Filed: March 15, 2005
    Date of Patent: July 29, 2014
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Michael T. Migawa, Walter F. Lima, Eric E. Swayze, Joshua Nichols, Hongjiang Wu, Thazha P. Prakash, Tadeusz Krzysztof Wyrzykiewicz, Balkrishen Bhat, Stanley T. Crooke
  • 5'-END DERIVATIVES
    Publication number: 20130323836
    Abstract: The present invention provides compounds of formula (1). Another aspect of the invention relates to a method of inhibiting the expression of a gene in call, the method comprising (a) contacting an oligonucleotide of the invention with the cell; and (b) maintaining the cell from step (a) for a time sufficient to obtain degradation of the mRNA of the target gene.
    Type: Application
    Filed: April 22, 2011
    Publication date: December 5, 2013
    Applicant: Isis Pharmaceuticals, Inc.
    Inventors: Muthiah Manoharan, Kallanthottathil G. Rajeev, Ivan Zlatev, Eric E. Swayze, Thazha P. Prakash, Walter F. Lima
  • METHODS OF DETERMINING POTENCY OF CHEMICALLY-SYNTHESIZED OLIGONUCLEOTIDES
    Publication number: 20130252243
    Abstract: Provided herein are methods for determining potency of RNAi agents. Such methods include, but are not limited to, cell-based and cell-free assays that measure binding of an RNAi agent with Ago2 or that measure Ago2 activity in the presence of such RNAi agents. Also provided are assays that determine potency of RNAi agents by assessing their ability to compete with other RNAi agents, including control RNAi agents, for binding and/or activation of Ago2.
    Type: Application
    Filed: December 21, 2012
    Publication date: September 26, 2013
    Applicant: Isis Pharmaceuticals, Inc.
    Inventors: Walter F. Lima, Timothy Vickers, Stanley T. Crooke
  • LIPID FORMULATED SINGLE STRANDED RNA
    Publication number: 20130156845
    Abstract: The present invention provides compositions comprising a nucleic acid lipid particle and an oligomeric compound and uses thereof. In certain embodiments, such compositions are useful as antisense compounds. Certain such antisense compounds are useful as RNase H antisense compounds or as RNAi compounds.
    Type: Application
    Filed: April 29, 2011
    Publication date: June 20, 2013
    Applicants: ALNYLAM PHARMACEUTICALS, INC., ISIS PHARMACEUTICALS, INC.
    Inventors: Muthiah Manoharan, Sayda Elbashir, Kallanthottathil G. Rajeev, Thazha P. Prakash, Walter F. Lima, Eric E. Swayze
  • Methods of determining potency of chemically-synthesized oligonucleotides
    Patent number: 8338185
    Abstract: Provided herein are methods for determining potency of RNAi agents. Such methods include, but are not limited to, cell-based and cell-free assays that measure binding of an RNAi agent with Ago2 or that measure Ago2 activity in the presence of such RNAi agents. Also provided are assays that determine potency of RNAi agents by assessing their ability to compete with other RNAi agents, including control RNAi agents, for binding and/or activation of Ago2.
    Type: Grant
    Filed: December 5, 2011
    Date of Patent: December 25, 2012
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Walter F. Lima, Timothy Vickers, Stanley T. Crooke
  • METHODS OF DETERMINING POTENCY OF CHEMICALLY-SYNTHESIZED OLIGONUCLEOTIDES
    Publication number: 20120077276
    Abstract: Provided herein are methods for determining potency of RNAi agents. Such methods include, but are not limited to, cell-based and cell-free assays that measure binding of an RNAi agent with Ago2 or that measure Ago2 activity in the presence of such RNAi agents. Also provided are assays that determine potency of RNAi agents by assessing their ability to compete with other RNAi agents, including control RNAi agents, for binding and/or activation of Ago2.
    Type: Application
    Filed: December 5, 2011
    Publication date: March 29, 2012
    Applicant: Isis Pharmaceuticals, Inc.
    Inventors: Walter F. Lima, Timothy Vickers, Stanley T. Crooke
  • Methods of determining potency of chemically-synthesized oligonucleotides
    Patent number: 8093061
    Abstract: Provided herein are methods for determining potency of RNAi agents. Such methods include, but are not limited to, cell-based and cell-free assays that measure binding of an RNAi agent with Ago2 or that measure Ago2 activity in the presence of such RNAi agents. Also provided are assays that determine potency of RNAi agents by assessing their ability to compete with other RNAi agents, including control RNAi agents, for binding and/or activation of Ago2.
    Type: Grant
    Filed: October 18, 2007
    Date of Patent: January 10, 2012
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Walter F Lima, Timothy Vickers, Stanley T Crooke